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Abstract
Spinal muscular atrophy (SMA) is a leading genetic cause of childhood mortality, caused by reduced levels of survival motor
neuron (SMN) protein. SMN functions as part of a large complex in the biogenesis of small nuclear ribonucleoproteins
(snRNPs). It is not clear if defects in snRNP biogenesis cause SMA or if loss of some tissue-specific function causes disease.
We recently demonstrated that the SMN complex localizes to the Z-discs of skeletal and cardiac muscle sarcomeres, and
that SMN is a proteolytic target of calpain. Calpains are implicated in muscle and neurodegenerative disorders, although
their relationship to SMA is unclear. Using mass spectrometry, we identified two adjacent calpain cleavage sites in SMN,
S192 and F193. Deletion of small motifs in the region surrounding these sites inhibited cleavage. Patient-derived SMA
mutations within SMN reduced calpain cleavage. SMN(D44V), reported to impair Gemin2 binding and amino-terminal SMN
association, drastically inhibited cleavage, suggesting a role for these interactions in regulating calpain cleavage. Deletion of
A188, a residue mutated in SMA type I (A188S), abrogated calpain cleavage, highlighting the importance of this region.
Conversely, SMA mutations that interfere with self-oligomerization of SMN, Y272C and SMND7, had no effect on cleavage.
Removal of the recently-identified SMN degron (D268-294) resulted in increased calpain sensitivity, suggesting that the C-
terminus of SMN is important in dictating availability of the cleavage site. Investigation into the spatial determinants of SMN
cleavage revealed that endogenous calpains can cleave cytosolic, but not nuclear, SMN. Collectively, the results provide
insight into a novel aspect of the post-translation regulation of SMN.
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Introduction
Spinal Muscular Atrophy (SMA) is an autosomal recessive
disorder and a leading genetic cause of childhood mortality
[1,2,3]. SMA falls into three clinical classes: types I, II and III,
based on the age of disease onset and phenotypic severity. It is
characterized by a loss of lower spinal motor neurons and atrophy
of the trunk and proximal limb muscles [4,5]. The locus
responsible for SMA was mapped to chromosome 5q13 [6,7]. In
humans, there are two genes, SMN1 (telomeric) and SMN2
(centromeric), located near each other at this locus [8]. The
protein coding sequences of SMN1 and SMN2 are predicted to be
identical, as SMN2 differs from SMN1 by only five nucleotides
[9,10]. In SMN2, a single C to T transition in exon 7 leads to
aberrant splicing, producing primarily transcripts lacking exon 7
(SMND7) [11,12]. The resultant SMND7 protein is not fully
functional and is less stable than full-length SMN [13,14,15,16].
The severity of SMA is inversely proportional to SMN2 copy
number. This is due to the ability of SMN2 to produce low levels
(,10%) of full-length SMN protein [17,18]. Over 96% of SMA
patients have homozygous mutations (deletion, rearrangement, or
point mutation) in SMN1, however they retain at least one copy of
SMN2 [8,19]. These findings suggest that SMN2 partially rescues
the lethal SMN1 loss-of-function phenotype, a hypothesis that has
been substantiated by mouse models of SMA [20,21].
SMN is thought to be involved in both tissue-specific and cell-
essential functions. While global functions of SMN include the
biogenesis of the small nuclear ribonucleoproteins (snRNPs) that
carry out pre-mRNA splicing [22,23], the putative tissue-specific-
functions include axonal mRNA transport, neurite outgrowth,
neuromuscular junction (NMJ) formation, myoblast fusion and
myofibril integrity [24,25,26,27,28,29]. The most well-character-
ized function of SMN is its role in snRNP biogenesis [30,31].
During snRNP biogenesis SMN primarily associates with eight
proteins, Gemins 2-8 and UNRIP/STRAP, to form the ‘‘SMN
complex.’’ Following SMN-assisted RNP assembly, spliceosomal
snRNPs are imported into the nucleus where they are further
modified and remodeled in distinct nuclear subdomains, termed
Cajal bodies (CBs). The snRNPs are subsequently released from
the SMN complex and transit to interchromatin granule clusters
[32]. It is currently unclear whether defective snRNP assembly
and subsequent splicing of genes in motoneurons is responsible for
SMA or if deficiencies in other tissue-specific functions of SMN
cause the disease [33].
We previously demonstrated that the SMN complex localizes to
both skeletal and cardiac myofibril Z-discs and interacts with a-
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actinin, an actin crosslinking protein [26,34]. Treatment of skeletal
myofibrils with exogenous calpain protease releases SMN from the
sarcomere, identifying it as a calpain substrate. SMN is a
proteolytic target of calpain, even when present in the native
SMN complex [34]. Calpains are calcium-activated neutral
cysteine proteases that are involved in numerous cellular processes,
including myogenesis, muscle remodeling, and synaptic function
(reviewed in [35,36,37,38,39,40]). Calpains typically perform
limited cleavage of their substrates, regulating their activity.
Fourteen distinct calpains have been identified in humans,
however the best characterized are the ubiquitous Calpain1 (m-
Calpain) and Calpain2 (m-Calpain). These large subunits
(,80 kDa) form heterodimers with a common small (,28 kDa)
regulatory subunit, called Calpain4. Calpains 1 and 2 are activated
by micro- and milli-molar levels of calcium, respectively, and are
inhibited in vivo by the protein calpastatin. Currently, it is unclear
how the calpain-calpastatin system is regulated in vivo, however
several possible modes of regulation have been proposed, such as
local calcium transients, differential localization, post-translational
modifications, and membrane association [37,41,42].
Calpains have been implicated in several muscle and neurode-
nerative disorders, including limb girdle muscular dystrophy type
2A (LGMD2A) [43], muscle cachexia [44], amylotrophic lateral
sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, cerebral ischemia and
prion-related encephalopathy [45]. Whether calpains play a role in
SMA is not known. To further characterize the relationship
between calpain and SMN, we characterized several determinants
of cleavage activity. In vitro peptide mapping showed that Calpain1
cleaves SMN after residues S192 or F193, proximal to a proline-
rich region; we determined that residues within a nearby PEST
motif are important for this cleavage. Calpain was blocked by
overexpression of calpastatin, but not by a D252A mutation,
which reportedly blocks caspase cleavage of SMN [46]. Several
SMA patient mutations residing in the N-terminus revealed a
reduction in calpain susceptibility. One mutation, D44V, reported
to inhibit Gemin2 binding [47], blocked calpain cleavage almost
entirely. SMA mutations that affect the self-oligomerization
properties of SMN, such as Y272C and SMND7, had no major
effect on cleavage, whereas increased calpain cleavage was
observed by removal of the recently identified SMN degron
(D268-294) [48]. Interestingly, an uncharacterized SMA mutation
residing near the calpain cleavage sites, A188S, modestly reduced
cleavage, and its deletion drastically impaired it, suggesting that
this region is important for calpain cleavage. Finally, we
determined that SMN is cleaved by cytosolic, but not nuclear
calpains, suggesting a possible role for calpain in cytoplasmic
regulation of SMN.
Materials and Methods
Cell culture, transfection, and DNA constructs
U2-OS osteosarcoma cells (American Type Culture Collection)
were grown in DMEM supplemented with 10% fetal bovine
serum, penicillin, and streptomycin at 37uC under 5% CO2.
Transient transfection of plasmid DNA was performed using
EffecteneH transfection reagent, per manufacturer’s instructions
(Qiagen). Cells were harvested 24–36 hrs. post-transfection.
Construct pEGFPC3-1-SMN was cloned by PCR amplification
of hSMN1 from previously constructed GFP-SMN* [49]. The
PCR product was cloned into pCRHII-TOPOH (Invitrogen), per
manufacturer’s instructions, to create pCRII-TOPO-SMN, and
subcloned into pEGFP-C3 (Clontech) using BglII and SalI
sites. The plasmid used to express and copurify HIS6SMN/
GST-Gemin2 heterodimers was created by first amplifying
hGemin2 by PCR from pcDNA3-Flag-Gemin2 [50]. The PCR
product was cloned into pCRHII-TOPOH (pCRII-TOPO-Ge-
min2) and the hGemin2 insert was digested with BglII and EcoRI
enzymes and ligated to BamHI and EcoRI digested pGEX-3X
(GE Healthcare) (pGEX3X-Gemin2). GST-Gemin2 was amplified
by PCR and subcloned into pCDFDuet-1 (Novagen) using NdeI
and XhoI sites (pCDFDuet1-GSTGemin2). Finally, hSMN1 was
digested with BglII and SalI enzymes from PCRII-TOPO-SMN
and subcloned into BamHI and SalI digested pCDFDuet1-
GSTGemin2 (pCDFDuet1-HIS6SMN-GSTGemin2). All dele-
tions and point mutations in this study were created in
pEGFPC3-1-SMN, by QuikchangeH site-directed mutagenesis,
per manufacturer’s instructions (Stratagene). Primer sequences for
all cloning and mutagenesis are available upon request. GFP-
hCalpastatin and HA-hCalpastatin containing plasmids were kind
gifts from Dr. Francesca Demarchi [51].
Cell-free calpain assays
To prepare lysate, cell pellets were resuspended in ice-cold
gentle binding buffer (50 mM Tris-HCl, pH 7.5, 200 mM NaCl,
0.2 mM EDTA, 0.05% NP-40) lacking protease inhibitors and
pushed 10 times through a syringe fitted with a 25.5 gauge needle.
The lysate was centrifuged at 14,000 RPM for 5 min. at 4uC. The
total protein concentration of the supernatant was determined by
Bradford assay using BSA as a standard [52]. Calpain assays were
performed using 30 mg of total protein in a total reaction volume
of 20 mL. Cleavage by endogenous calpains was activated by the
addition of 1 mM CaCl2. Where indicated, exogenous Calpain1
(porcine erythrocytes, Calbiochem) and 1 mM CaCl2 were added.
Calpain inhibitors N-acetyl-leucyl-leucyl-norleucinal, ALLN (Cal-
biochem) (inhibited cleavage at both 10 mM or 1 mM), and EGTA
(4 mM) were added prior to the addition of calcium or exogenous
Calpain1. Reactions were incubated for 15 min. (10 min. for
reactions used for quantification) at 30uC and terminated by the
addition of 5X SDS sample buffer (250 mM Tris-HCl, pH 6.8,
10% SDS, 50% glycerol, 500 mM DTT, 0.1% bromophenol
blue), and heating at 100uC for 5 min.
Cell fractionation
U2-OS cells were harvested and fractionated using the NE-
PERH nuclear and cytoplasmic extraction reagents, per manufac-
turer’s instructions, in the absence of protease inhibitors (Thermo
Scientific). The nuclear lysates were dialyzed at 4uC in gentle
binding buffer. Total protein concentration in the lysates was
determined by Micro BCATM Protein assay (Thermo Scientific).
Calpain cleavage assays utilizing cytoplasmic and nuclear lysates
were performed as described above.
Western analysis and quantification of calpain cleavage
Proteins were separated by SDS-PAGE and transferred onto
nitrocellulose (Whatman). Mouse monoclonal antibodies recog-
nizing either the N-terminus (clone 8, BD Biosciences, 1:10,000) or
the C-terminus (9F2, L. Pellizzoni, 1:10) of SMN were used.
Rabbit polyclonal antibodies recognizing GAPDH (IMGENEX,
1:4,000) or GFP (Invitrogen 1:2,000) were also used. The
appropriate secondary antibodies conjugated to HRP (Thermo
Scientific, 1:5,000-10,000) were used to obtain representative film
images. To determine relative calpain susceptibilities of GFP-SMN
constructs, quantification of full-length and N-terminal cleavage
products was performed. While detectable by chemiluminescence,
the C-terminal SMN cleavage product was not readily detected by
fluorometry and thus was not used for quantification. The N-
terminal SMN antibody, followed by a secondary antibody
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conjugated to Cy3 (GE Healthcare, 1:4000) was used for
quantification of calpain cleavage by fluorometry using unsatu-
rated digital scans performed on a Typhoon Trio+ Variable Mode
Imager (GE Healthcare). The integrated density of the full-length
EGFP-SMN and the N-terminal cleavage product were quantified
using ImageJ (http://rsbweb.nih.gov/ij/). Background signal was
subtracted using the default rolling ball parameters. The percent
cleavage of EGFP-SMN for each reaction was calculated by
dividing the integrated density of the N-terminal cleavage
fragment over the sum of the integrated density of the two bands.
The average fraction cleaved was determined from six indepen-
dent cell-free calpain assays.
Purification and calpain cleavage of SMN/Gemin2
heterodimers
The pCDFDuet1-HIS6SMN-GSTGemin2 construct was trans-
formed into BL21 StarTM (DE3) E. coli (Invitrogen). Cells were
grown in 2 L LB containing streptomycin (50 mg/ml) at 37uC and
induced with 1 mM IPTG (ACROS) at 30uC for 4 hr. Cells were
harvested by centrifugation at 4uC for 10 min. at 3,500 RPM
(F10S-6x500y rotor, Thermo Scientific) and resuspended in PBS
containing protease inhibitors (Roche). Cells were lysed by
sonication and incubated with 1% Triton X-100 for 30 min. at
4uC. Lysate was clarified by centrifugation at 4uC for 15 min. at
10,000 RPM (SLA-600 rotor, Sorvall). Clarified lysate was mixed
with 600 ml bed volume Glutathione SepharoseTM4B beads (GE
Healthcare) at 4uC for 3 hr. Protein bound beads were washed
extensively with PBS +1% Triton X-100 and subsequently PBS
+0.1% Triton X-100, and stored O/N at 220uC in PBS +75%
glycerol +0.1% Triton-X100. In vitro cleavage of HIS6SMN/GST-
Gemin2 was performed by first equilibrating the protein bound
beads in RSB100 + Ca2+ buffer (10 mM Tris-HCl, pH 7.5,
2.5 mM MgCl2, 100 mM NaCl, 0.1% NP-40, 1 mM CaCl2) by
extensive washing. Equal volumes of protein-bound beads were
then shaken (500 RPM) in the absence or presence of Calpain1
(1U or 2U) (Calbiochem) in 40 ml reactions for 1 hr. at 30uC.
Reactions were terminated by adding 1% SDS and heating at
100uC for 10 min. The volume was increased to 200 ml with H2O
and the samples were vortexed to further elute the proteins. The
beads were pelleted by centrifugation and the supernatants were
reduced in volume to 40 ml by vacuum. Proteins were reduced by
incubating with 10 mM DTT (Fisher Scientific) at 50uC for 15 min.
and subsequently alkylated by incubating with 50 mM iodoaceta-
mide (Sigma) at room temperature for 30 min. in the dark.
Peptide fingerprint analysis
HIS6SMN/GST-Gemin2 heterodimers were cleaved with
Calpain1, as described above, and samples were mixed with 5X
SDS sample buffer and proteins were separated by SDS-PAGE.
The gel was stained with GelCodeH Blue Stain, per manufactur-
er’s instructions (Thermo Scientific), and submitted to the UNC
Michael Hooker Proteomics Center for analysis. Individual gel
bands were then manually excised and subjected to overnight-
automated digestion with sequencing grade modified trypsin
(Promega) on a ProGest Digestor (Genomic Solutions) at 37uC.
Resultant peptides were lyophilized and re-dissolved in 5 uL of
50% methanol/0.1% trifluoroacetic acid (TFA). Peptides were
spotted onto a MALDI target plate with an equal volume of a-
cyano-4-hydroxycinnamic acid matrix solution and allowed to air
dry. Mass spectrometry was carried out on a 4800 Plus MALDI
TOF/TOF Analyzer (Applied Biosystems). Peptides were scanned
in positive reflector mode over the mass range 700–4000 m/z,
with internal calibration against trypsin peaks 842.51 and
2211.105 m/z. The forty most intense peptides were automatically
selected for MS/MS analysis. Peptide mass and corresponding
MS/MS fragmentation information for each sample were
searched against the HIS6-SMN1 protein sequence using Mascot
(Matrix Science) and GPS Explorer (Applied Biosystems).
Results
Exogenous and endogenous calpains cleave SMN to
produce distinct cleavage products
We previously demonstrated that SMN is a target of calpain.
Calpain cleavage of both native and recombinant SMN complexes
leads to production of N- and C-terminal cleavage products.
However, we had been unable to detect the C-terminal cleavage
product in cell-free cleavage assays using HeLa cell lysates [34].
Subsequently, we found that addition of exogenous calpain in cell-
free cleavage assays using U2-OS osteosarcoma cells results in a
clearly detectable C-terminal cleavage product. Increased levels of
exogenous calpain can lead to further cleavage and proteolysis of
SMN (Fig. 1A), however whether this degree of proteolysis occurs
in vivo is unknown. To confirm that calpains are responsible for the
observed cleavage, we transiently expressed the calpain inhibitor
calpastatin into U2-OS cells and performed cell-free cleavage
assays. While several peptidyl inhibitors are commonly used to
inhibit calpain, their inhibition is not limited to calpain proteases
[53]. We therefore expressed calpastatin, which is the only known
specific endogenous inhibitor of calpain [54]. Although the assay
was not as robust (see Methods), we observed the C-terminal
cleavage product upon treatment with calcium alone, demon-
strating that cleavage by endogenous calpains also produces both
cleavage products (Fig. 1B). Considering the amount of full-length
SMN remaining after the addition of calcium, it is likely that only
a small population of SMN proteins interact with endogenous
calpains under these experimental conditions. Overexpression of
GFP-Calpastatin or HA-Calpastatin blocked cleavage of SMN
(Fig. 1B and data not shown), confirming that calpain is
responsible for the calcium-activated cleavage of SMN in vivo.
These results suggest that cleavage of SMN by calpain, and/or the
stability of the cleavage products, may vary among cell types.
Considering that calpains are generally thought to be regulatory
proteases versus degradative ones [37], the detection of the
cleavage products opens up the possibility that they may be stable
enough to function in the cell. Notably, overexpression of the
SMN C-terminus (amino acids 235-294) is reportedly sufficient to
rescue neurite outgrowth [27], further supporting this notion.
Calpain cleavage of SMN is distinct from caspase
cleavage of SMN
Caspases and calpains are cysteine proteases involved in
apoptosis, although the role of calpains in this process is not well
defined [55]. The two protease families regulate each other
directly, as well as through cleavage of the calpain inhibitor,
calpastatin [56,57,58]. Virus-induced apoptosis and neuronal
injury produce an N-terminal SMN cleavage product (,29 kDa)
and mutation of a predicted caspase cleavage site, D252A, blocks
this cleavage [46]. SMN cleavage products, presumably due to
caspase cleavage, are also generated in PC12 cells after
deprivation of trophic support [59], further suggesting SMN is
cleaved during apoptosis. To determine if the cleavage products
we observed were different from the reported caspase cleavage
product, we assayed the cleavage susceptibility of SMN(D252A) in
cell-free cleavage assays. EGFP-SMN and EGFP-SMN(D252A)
were transiently expressed in U2-OS cells, and cell lysates were
incubated in the absence or presence of CaCl2 to activate
endogenous calpains. Western analysis performed with antibodies
Calpain Cleavage of SMN
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that recognize either the N- or C-terminus of SMN showed that
both WT and mutant SMN proteins were cleaved by calpain, and
cleavage was blocked by pre-incubation of lysates with a calcium
chelator (EGTA) or with a calpain inhibitor (ALLN, N-acetyl-Leu-
Leu-norleucinal) [53] (Fig. 1C). These results indicate that the
calpain cleavage site in SMN is distinct from the previously
reported caspase cleavage site.
Identifying sequence determinants of SMN cleavage
Calpains recognize the tertiary structures of their substrates, and
although there is no consensus recognition sequence, certain
amino acids are preferred at the scissile peptide bond
[60,61,62,63]. In addition, the presence of PEST motifs, initially
identified in short-lived proteins, often indicate the presence of
nearby calpain proteolytic sites [64,65]. PEST domains are regions
rich in proline (P), glutamic acid (E), serine (S), and threonine (T)
and can be computationally predicted. Analysis of SMN (http://
mobyle.pasteur.fr/cgi-bin/portal.py?form = epestfind) reveals that
it contains one strong (aa133-174), and three weak PEST (aa1-22,
aa97-119, aa227-273) motifs (Fig. 2A). The strong PEST motif
partially overlaps with the conserved Tudor domain (Fig. 2A),
which interacts with RG-rich domains, such as those found on Sm
proteins and the Cajal body marker protein, Coilin
[66,67,68,69,70]. Considering the size of the SMN cleavage
products (,28 and ,10 kDa), their differential reactivity to
antibodies against the N- or C-terminus of SMN, and that calpain
protease sites can reside within or adjacent to PEST motifs
[64,65], we predicted that sequences within SMN exons 4 or 5
contain the calpain cleavage site. This predicted calpain cleavage
region (CCR) is downstream of the strong PEST motif and
overlaps with the proline-rich region (Fig. 2A) that was shown to
interact with the actin-binding protein, profilin [71,72].
To identify amino acids in SMN that are important for calpain
cleavage, we created constructs containing internal deletions in
EGFP-SMN and tested their susceptibility to calpain cleavage in
cell-free assays. Deletions targeted the Tudor domain (aa91-151),
the strong PEST motif (aa133-174), and the CCR (aa175-226). The
results demonstrate that the PEST motif and CCR are necessary
for calpain cleavage, whereas the Tudor domain is dispensable
(Fig. 2B). To determine if a smaller region of the PEST motif is
sufficient to direct cleavage, we made smaller internal truncations.
These deletions overlapped with the Tudor domain (aa133-151),
with exon 3 (aa152-174), or did not overlap with either region
(aa159-174). Smaller deletions within the PEST motif failed to
block calpain cleavage of SMN (Fig. 2C), suggesting that the entire
PEST motif is not necessary to direct calpain cleavage.
Analysis of smaller internal deletions in the CCR showed that
deletion of amino acids 175-199, 175-194, 195-226, or 183-211 all
blocked the calpain cleavage of SMN, whereas deletion of residues
200–226 did not. The C-terminal cleavage product of EGFP-
SMND200-226 was not detected by the anti C-terminal SMN
antibody (Fig. 2D). This could result from deletion of the antibody
epitope (which resides within aa188-268, L. Pellizzoni, personal
communication), or from destabilization of the C-terminal
product. Thus, the CCR could be narrowed down to amino acids
183-194; additional mutations within this twelve amino acid
window substantially blocked calpain cleavage. As summarized in
Fig. 2E, the smallest, non-overlapping deletions that inhibited
cleavage were residues 183–189 (IKPKSAP), and 192-194 (SFL).
Note that several of the deletions removed a stretch of five proline
Figure 1. Western analysis of calpain assays detects two SMN cleavage products. (A) 1 mM CaCl2 and the indicated units of Calpain1 were
incubated with U2-OS cell lysates. 30 mg total protein was used in each reaction. Both N-terminal and C-terminal cleavage products were observed
with the indicated SMN antibodies (left). (B) Cells were mock transfected or transfected with either EGFP empty vector or EGFP-Calpastatin (CAST).
Lysates were incubated in the absence (-) or presence (+) of 1 mM CaCl2 to activate SMN cleavage by endogenous calpains. Overexpression of
calpastatin blocked calpain cleavage of SMN. (C) Cells were transfected with either EGFP-SMN or EGFP-SMN(D252A) and 1 mM CaCl2 (+, E, I) was
added to the lysates. Where indicated, calpain cleavage was inhibited by addition of EGTA (E) or ALLN (I). Full-length GFP-SMN and cleavage products
were detected by Western analysis using either N- or C-terminal SMN antibodies. As expected, the mock-transfected sample (M) did not contain GFP-
tagged proteins. GAPDH was used as a loading control. *In the absence of calpain activation and protease inhibitors EGFP-SMN was subject to
unknown protease(s), unrelated to calpains. Calpain cleavage products of EGFP-SMN that correlated to those observed upon calpain cleavage of
endogenous SMN were studied.
doi:10.1371/journal.pone.0015769.g001
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residues (P195-P199) in proline-rich region (Fig. 2A–E). Consid-
ering the importance of proline in protein secondary structures, we
assayed whether mutation of these residues affected cleavage.
However, we found that deletion or substitution by alanine or
glycine residues did not block calpain cleavage (Fig. S1), suggesting
that these putative structural changes were not significant enough
to block cleavage.
Mapping the calpain cleavage site
Using mutational analysis, we successfully refined the CCR to
amino acids 183-189 or 192-194, however it remained unclear
whether these residues corresponded to the cleavage site or if they
simply affected cleavage by another means. To precisely map the
calpain cleavage site, we performed in vitro calpain cleavage
reactions using purified recombinant HIS6-SMN/GST-Gemin2
heterodimers followed by mass spectrometric analysis of the C-
terminal cleavage product. HIS6-SMN/GST-Gemin2 was co-
expressed in E. coli and purified using glutathione sepharose beads.
Gemin2 is a binding partner [22,73] of SMN and was co-
expressed to aid in SMN solubility in E. coli [74]. HIS6-SMN/
GST-Gemin2 heterodimers were left either untreated, or were
incubated with 1 mM CaCl2 and exogenous Calpain1 at 30uC.
Figure 2. Sequence determinants of calpain cleavage of SMN. (A) Schematic of SMN protein, showing relevant domains and amino acids. The
Tudor domain, proline-rich (P-rich) region, and YG box are labeled. Solid and dotted lines indicate the strong and weak PEST motifs, respectively. The
calpain cleavage region (CCR) and mapped calpain cleavage site (CCS) are labeled. (B-F) Internal deletions were created in EGFP-SMN and transiently
expressed in U2-OS cells. Endogenous calpain cleavage assays and subsequent Western analysis was performed to determine calpain cleavage
susceptibility. Full-length GFP-SMN and cleavage products were detected using N- or C-terminal SMN antibodies. (B) The PEST motif and CCR are
necessary for calpain cleavage, whereas the Tudor domain is dispensable. (C) Smaller deletions within the PEST domain allow for calpain cleavage.
The entire PEST motif is not necessary for calpain cleavage. (D–E) Sequence determinants of calpain within the CCR. The CCR was progressively
refined within residues 183–189 and 192–194.
doi:10.1371/journal.pone.0015769.g002
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Cleavage products were analyzed on Coomassie stained SDS-
PAGE gels and by Western blot. As previously demonstrated,
Calpain1 cleavage of HIS6-SMN/GST-Gemin2 heterodimers
produced the expected SMN cleavage fragments (Fig 3A,B and
S2; [34]). The C-terminal cleavage product was excised, digested
with trypsin, and the resultant peptides were subjected to MALDI
MS/MS. Peptide fingerprint analysis identified nine different
peptides in the calpain-treated samples (Table 1, Fig. S3, S4). As
expected, no SMN peptides were obtained from the excised gel
slice from the untreated sample. Among the nine peptides
identified in the treated samples, three sequences (in italics) were
represented, S192*FLPPPPP-MPGPR*L205, F193*LPPPPPMPGP-
R*L205, and R204*LGPGKPGLK*F214 (asterisks indicate cleavage
sites). Trypsin cleaves after arginines and lysines. Therefore the
first two peptides, which each have one non-tryptic end, indicate
that calpain cleaves SMN after S192 or F193. The tryptic peptide,
R204*LGPGKPGLK*F214, is immediately downstream of these
peptides. Several other theoretical tryptic peptides were not
detected due to their size. Only one expected tryptic peptide,
R288*CSHSLN, was not identified. The mapped cleavage sites are
in agreement with recognized amino acid preferences of calpain
[60,63] and several calpain cleavage prediction models, two of
which predict F193 as the most probable calpain cleavage site in
SMN. These models also predict S192 as a probable calpain
cleavage site (see Calpain Modulatory Proteolysis Database,
http://www.calpain.org/predict.rb?cls = substrate; [75]).
To further verify the results, we created double and single
deletions within amino acids 192-194 in EGFP-SMN and assayed
calpain susceptibility in endogenous calpain assays. Western
analysis revealed that double deletions of S193,F193 (DSF) or
F193,L194 (DFL) were capable of inhibiting calpain cleavage,
whereas single deletions were not (Fig. 3C). Deletion of nearby
residues (D177-182, D212-215) containing other putative calpain
cleavage sites did not block SMN cleavage (data not shown).
Altogether, these data reveal S192 and F193 as bona fide calpain
cleavage sites.
Removal of the SMN C-terminus, not SMN-
oligomerization, affects calpain cleavage
The conserved YG box in SMN, with the aide of sequences
corresponding to exon 2b, is important for the formation of SMN
oligomers [47,76,77,78], which are important for SMN complex
formation and stability [13,47]. SMA type I point mutations
within the YG box (Y272C, G279V) disrupt this self-association,
whereas SMA type II and III mutations (S262S, T274I), as well as
SMND7, show intermediate oligomerization defects [76]. The
reduced stability of SMND7 was recently proposed to be due to
the presence of a degradation signal encoded by the YG box along
with the residues EMLA [48], which are translated from exon 8 of
the SMN2 gene [79]. To determine if calpain cleavage could also
play a role in SMN stability, we created mutations in the C-
terminus of EGFP-SMN and assayed their susceptibility to
endogenous calpains.
To quantify differences in calpain cleavage, we performed
Western analysis using N-terminal SMN antibodies followed by
Cy3-conjugated secondary antibodies. Using fluorometry, we
quantified non-saturated signals from the full-length and the N-
Figure 3. Mapping the calpain cleavage site. (A) Coomassie stained gel of HIS6-SMN/GST-Gemin2 heterodimers cleaved in vitro with indicated
units of Calpain1 for 1 h. at 30uC. Full-length SMN (FL-SMN) as well as the N-terminal (N-SMN) and C-terminal (C-SMN) cleavage products are indicated
with arrows. The C-terminal cleavage fragments were subjected to peptide fingerprint analysis. Asterisks (*) indicate full-length and truncated GST-
Gemin2 proteins (see Fig. S2). (B) Western blot analysis of in vitro calpain assays. Antibodies recognizing the N- or C-terminus of SMN detected FL-
SMN and SMN calpain cleavage products. The fraction of SMN cleavage was directly proportional to the amount of exogenous Calpain1 added. (C)
Endogenous calpain cleavage assays were performed with EGFP-SMN containing small deletions within the calpain cleavage site. Double deletions
blocked calpain cleavage, whereas single deletions did not.
doi:10.1371/journal.pone.0015769.g003
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terminal EGFP-SMN calpain cleavage product. We calculated the
average fraction of calpain cleavage observed for each mutant as
compared to WT cleavage. To examine if SMN oligomerization
defects perturbed calpain cleavage, we assayed two YG box
mutant proteins, Y272C and T274I. We found that neither
mutation affected calpain susceptibility, suggesting that monomer-
ic SMN is not a better substrate for calpain cleavage (Fig. 4A,B).
The calpain susceptibilities of SMND7 and SMND7+EMLA
proteins were also similar to that of WT (Figs. 4A,B, and S5),
indicating that calpain cleavage is not a primary contributor to the
instability of SMND7. Interestingly, we observed that deletion of
the C-terminus, including the YG box (DYG+, D268-294), renders
SMN more susceptible to calpain cleavage (Fig 4A,B). This
increase suggests that the structure of the C-terminus affects the
availability of the calpain cleavage site. In addition, removal of the
SMN degron may not protect SMN from all proteases in the cell.
Together, these results suggest that calpain is not a major
determinant of SMN or SMND7 stability in cultured cells.
Patient-derived SMA mutations exhibit reduced calpain
cleavage susceptibility
Although many SMA missense mutations reside in exons 6 and
7 of SMN1, others have been identified in exons 1-4. Character-
ization of a few of these mutant proteins has revealed that,
although their ability to self-associate remains intact, they disrupt
protein-protein interactions and can inhibit snRNP assembly [33].
We thus created various SMA mutations in EGFP-SMN and
assayed their calpain cleavage susceptibility in endogenous calpain
cleavage assays.
The SMN-Gemin2 interaction is thought to provide a scaffold
onto which other SMN complex components assemble [80,81].
Gemin2 makes multiple contacts with SMN. It interacts with the
region encoded by exon 2b [78] and the SMN-Gemin2 interaction
is disrupted by competition with an N-terminal SMN peptide
(aa13-44) or in the absence of the SMN N-terminus (D1-39)
[73,82]. Two SMA mutations in exon 2a show different
characteristics. An SMA type II mutation (D30N) associates with
WT SMN, interacts with Gemin2, and supports normal snRNP
assembly, whereas these properties are disrupted by the SMA type
III mutation SMN(D44V). Disruption of the SMN-Gemin2
interaction destabilizes the SMN complex. These effects are more
pronounced when assayed in the backbone of the SMN exons1-5
truncation (SMNex1-5) versus full-length SMN, presumably due to
the absence of the C-terminal self-association domain [47,83]. We
assayed whether these mutations also had differences in calpain
susceptibility using the cell-free system described above. Due to
disruption of the epitope, the N-terminal anti-SMN antibody did
not detect EGFP-SMN(D44V), so we used antibodies targeting
GFP to examine cleavage of this mutant (Fig 5A). The EGFP-
SMN(D30N) mutant showed similar cleavage susceptibility to
WT, whereas the cleavage of D44V was dramatically inhibited
(Fig. 5A,B). The results suggest that disruption of Gemin2 and/or
SMN amino-terminal self-interactions alter the availability of the
calpain cleavage site. When these mutations were assayed in the
backbone of an EGFP-SMNex1-5 truncation, the D44V mutation
no longer blocked calpain cleavage, further supporting a role for
the C-terminus in regulating availability of the cleavage site (Fig.
S6).
The Tudor domain is a conserved motif found in several RNA
binding proteins, including SMN [84]. The SMN Tudor domain
is involved in binding several RG/RGG containing proteins,
including the Sm proteins that are essential for snRNP assembly
[66,67,68,70]. Several mutations in the Tudor domain have been
identified in SMA type I patients, three of which (I116F, E134K,
and Q136E) were previously demonstrated to display reduced
snRNP assembly activity [49]. We assayed calpain susceptibility of
these mutations, along with the A111G mutation, which has
normal snRNP assembly activity and moderate Sm protein and
SMN association ability [49,85]. We found A111G did not affect
calpain susceptibility, whereas the I116F, E134K, and Q136E
mutations showed slightly reduced calpain cleavage (Fig. 5C,D).
Interestingly, the relative calpain susceptibility of the mutants
shows the same trend as their relative snRNP assembly efficiencies.
This raises the possibility that structural changes imposed by these
mutations affect both snRNP assembly and calpain cleavage.
We demonstrated that EGFP-SMND183-189, which neighbors
the calpain cleavage site, was not cleaved by calpain (Figs. 2E, 5E).
Previously, an SMA type I patient was found to have an A188S
mutation in SMN1 [86]. Although the A188S mutation slightly
reduced calpain cleavage, deletion of this residue (D188) greatly
impaired calpain cleavage, supporting the importance of this
Table 1. Peptide fingerprint analysis of C-terminal SMN cleavage product.
Peptide Source SMN Peptide Identified
Tryptic/
Non-tryptic Peptide m/z MASCOT Ion Score
Untreated None NA NA NA
1U Calpain1 S192*FLPPPPPMoxPGPR*L205 Non-tryptic 1318.7067 9
F193*LPPPPPMPGPR*L205 Non-tryptic 1155.6343 56
F193*LPPPPPMoxPGPR*L205 Non-tryptic 1171.6345 24
R204*LGPGKPGLK*F214 Tryptic 866.5449 40
2U Calpain1 S192*FLPPPPPMPGPR*L205 Non-tryptic 1302.7100 71
S192*FLPPPPPMoxPGPR*L205 Non-tryptic 1318.7010 27
F193*LPPPPPMPGPR*L205 Non-tryptic 1155.6340 65
F193*LPPPPPMoxPGPR*L205 Non-tryptic 1171.6300 47
R204*LGPGKPGLK*F214 Tryptic 866.5366 52
HIS6-SMN/GST-Gemin2 heterodimers were either untreated or cleaved with 1 or 2U of Calpain1. Bands containing the C-terminal calpain cleavage products were
excised and subjected to peptide fingerprint analysis. An equivalent area in the untreated control sample was also analyzed. Nine peptides were identified (italics), four
of which were in oxidized form (ox). Asterisks indicate the proteolytic cleavage sites. Non-tryptic peptides reveal the Calpain cleavage sites. Peptide m/z and MASCOT
ion scores for each peptide are reported.
doi:10.1371/journal.pone.0015769.t001
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region for calpain cleavage (Fig. 5E,F). Together, the results
demonstrate that certain SMA mutations can affect the calpain
cleavage susceptibility of SMN.
SMN is cleaved by cytoplasmic calpain
Calpains are considered to be cytoplasmic proteases; however
there have been reports of several calpains that also localize to the
nucleus [87,88,89,90,91]. Indeed, several nuclear proteins,
including transcription factors, have been demonstrated as in vitro
substrates of calpain. However, it is unclear if these proteins are
cleaved in the nucleus or in the cytoplasm prior to import
(reviewed in [37]). Like calpains, SMN also resides in the
cytoplasm and nucleus [92], raising the question of the location
of SMN cleavage. We therefore fractionated U2-OS cells into
cytoplasmic and nuclear lysates prior to treatment with CaCl2, or
with both CaCl2 and exogenous Calpain1. Western analysis
showed that endogenous (Fig. 6A) and exogenous Calpain1
(Fig. 6B) readily cleaved SMN in the cytoplasm, whereas nuclear
SMN was only cleaved upon addition of CaCl2 and exogenous
Calpain1. Interestingly, the amount of nuclear cleavage was
much less compared to cytoplasmic SMN cleavage, suggesting
nuclear SMN is resistant to calpain. This resistance is not likely a
result of experimental conditions, considering autolysis of
Calpain1 also occurred in the nuclear fractions [93], as shown
by a slight shift in the Calpain1 band size (Fig. 6A,B). Whether
resistance is due to properties of nuclear SMN, or due to the
activities of calpain and calpastatin within the nucleus is
unknown. Considering the complete cleavage of cytoplasmic
full-length SMN upon the addition of exogenous Calpain1 and
CaCl2, the levels of the N-terminal cleavage product were lower
than expected (Fig. 6B, lane 2). This may be the result of further
cleavage and subsequent degradation of the N-terminal product,
presumably due to the cell fractionation conditions and amount
of exogenous Calpain1 present. Regardless, these results show
that SMN is cleaved by endogenous calpains in the cytoplasm,
consistent with the idea that calpain regulates only cytoplasmic
functions of SMN.
Discussion
We have previously shown that recombinant HIS6-SMN/GST-
Gemin2 heterodimers and native SMN complexes are proteolytic
targets of calpain [34]. To identify determinants of calpain
cleavage, we analyzed the calpain susceptibility of mutant SMN
proteins that contained internal deletions or SMA-derived point
mutations. One identified determinant was the PEST motif, whose
presence often indicates the existence of a nearby proteolytic
cleavage site [64,65]. Deletion of the PEST motif (aa133-174) in
SMN blocks calpain cleavage, indicating that it is an important
determinant of cleavage (Fig. 2B). However, the entire PEST motif
is not necessary to direct calpain cleavage, as smaller deletions
within this region do not block cleavage (Fig. 2C). Furthermore,
deletion of the conserved Tudor domain (aa91-151), which
partially overlaps with the PEST motif, does not block calpain
cleavage (Fig. 2B). Interestingly, three SMA patient mutations
within the Tudor domain (I116F, E134K, and Q136E), two of
which also reside in the PEST motif, slightly impair calpain
cleavage (Fig. 5C,D). These mutations are known to interfere with
various protein interactions, such as with Sm proteins
[66,67,68,70], Fibrillarin [94], Gar1 [95], EBNA2 [96], hnRNPR
[97], EWS [98], and KSRP/FBP2 [99]. Whether disruption of
these or other interactions correlates with decreased calpain
cleavage is currently unknown. It is possible that such interactions
are necessary for SMN to maintain the optimal conformation for
calpain cleavage. It is important to note that mutations (Y272C
and SMND7) that interfere with snRNP assembly do not affect
calpain cleavage (Fig. 4A,B).
We found that residues within the N- and the C-termini of SMN
are important for cleavage. Association of SMN with the SMN
complex has been proposed to stabilize the protein [13,47]. It was
therefore of interest to determine if mutations that impair
oligomerization increase the susceptibility to calpain. We found
that such SMA patient mutations, Y272C, T274I, SMND7, did
not result in increased calpain susceptibility (Fig. 4A,B), suggesting
calpain does not play a major role in the stability of SMN. This is
consistent with the finding that treatment of cells with the calpain
inhibitor calpeptin does not increase overall SMN levels [13,48]
and with observations that overexpression of calpastatin does not
notably affect SMN levels or its localization in U2-OS (Fig. 2B and
data not shown). These data, however, do not exclude the
possibility that calpain might regulate a subpopulation of SMN
proteins (e.g. within axonal or dendritic spines or other
subdomains of the cytoplasm). Although removal of exon7 did
not affect calpain cleavage of SMN, we showed that removal of the
YG box along with exon7 (YG+), increased its susceptibility to
calpain cleavage (Fig. 4A,B). This suggests that the C-terminus of
SMN regulates the availability of the calpain cleavage site. Indeed,
removal of the SMN degron does not protect SMN from calpain
Figure 4. Deletion of the SMN C-terminus affects calpain cleavage. (A) A representative Western blot (for illustrative purposes only)
demonstrating the calpain cleavage susceptibility of several C-terminal mutants. (B) Quantification of GFP-SMN cleavage was determined from
Western blots probed with N-terminal SMN antibodies followed by Cy3 conjugated secondary antibodies (see Methods). The average fraction
(expressed as %) of calpain cleavage was calculated from six independent cell-free cleavage assays. Removal of amino acids 268-294 (DYG+) in SMN
renders it more susceptible to calpain cleavage, whereas mutations in the YG box or exon 7 (DEx7) did not. Error bars represent the SEM. Asterisks (**)
indicate p value ,0.001, determined by two-tailed Student T-test.
doi:10.1371/journal.pone.0015769.g004
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cleavage. It is noteworthy that the abundance of the C-terminal
cleavage products for several of the C-terminal mutants does not
reflect the levels of the corresponding N-terminal cleavage
products (Figure 4). These results may indicate a difference in
stability for these C-terminal cleavage products.
The importance of the C-terminus was also demonstrated by
the ability of calpain to cleave EGFP-SMNex1-5(D44V), but not the
full-length mutant protein. Calpain cleavage was drastically
impaired by the D44V mutation (Fig. 5A,B, S6). This mutation
lies within exon 2a and has been found to impair Gemin2 binding
[47]. Intriguingly, regions encoded by exons 2a and 2b, have been
proposed to form intramolecular contacts with sequences encoded
by exon 4 [78]. Thus, Gemin2, which is not itself a substrate for
calpain when present the SMN complex [34], may be important
for cleavage of SMN by calpain.
To map the calpain cleavage site, we implemented two
approaches. The first monitored the calpain cleavage of numerous
mutant proteins containing internal deletions within the CCR
(Fig. 2). The second utilized peptide fingerprint mapping of the C-
terminal cleavage product (Fig. 3A, 3B, S2). Identification of
peptides containing non-tryptic termini revealed that calpain
cleaves SMN after S192 or F193 (Table 1, Fig. S4, S5). Deletion of
either residue does not block cleavage, however deletion of
S192,F193 (DSF) or F193,L194 (DFL) blocked cleavage at these
sites. These results support the peptide fingerprinting data
(Fig. 3C). Interestingly, an uncharacterized SMA type I mutation,
A188S, resides immediately upstream of the calpain cleavage site.
This mutant protein is slightly less susceptible to calpain cleavage
and its deletion blocks calpain cleavage (Fig. 5E,F), further
demonstrating that this region of the protein is important for
Figure 5. SMA mutations affect calpain cleavage. (A, C, E) Illustrative Western blot demonstrating the calpain cleavage susceptibility of several
N-terminal mutants. (B, D, F) Quantification of GFP-SMN cleavage was determined from Western blots probed with N-terminal SMN antibodies
followed by Cy3 conjugated secondary antibodies (see Methods). The average % of calpain cleavage was calculated from six independent cell-free
cleavage assays. Error bars represent the SEM. Asterisks indicate p value, where p,0.005 (*) or p,0.001 (**), determined by two-tailed Student T-test.
(A, B) Calpain cleavage of SMN(D30N) was similar to WT, whereas SMN(D44V) was drastically reduced, below the limits of quantification. Therefore,
GFP antibodies were used only for detection of the EGFP-SMN(D44V) protein. (C, D) Three mutations within the Tudor domain (I116F, E134K, and
Q146Q) showed slightly reduced susceptibility to calpain cleavage, whereas A111G behaved similar to WT. (E, F) Calpain cleavage of A188S was
modestly reduced, but its deletion (DA188) greatly reduced calpain cleavage, below the limits of quantification.
doi:10.1371/journal.pone.0015769.g005
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cleavage (Fig. 2E). Conversely, mutation of the prolines immedi-
ately downstream of the cleavage site did not significantly affect
cleavage, suggesting there is some allowance for flexibility in
neighboring residues (Fig. S1).
Cleavage of SMN results in two products, 1-193 and 194-294,
fragments that contain the Tudor domain and proline-rich region,
respectively (Fig. 2A). Localization of these fragments in U2-OS
cells revealed a similar distribution to that of full-length SMN (data
not shown). In contrast, similar SMN constructs (aa1-194 and
aa190-294), were shown to have a pan-cellular localization in
COS-1 cells, however, both constructs failed to localize to nuclear
bodies [100]. It is possible that the differences in localization are a
result of experimental conditions, including the cell lines and
epitope tags used. It is currently unknown how calpain cleavage
affects SMN function, however, it is tempting to speculate that
calpain cleavage could lead to altered protein interactions or might
regulate an activity of the SMN complex through incorporation of
the cleavage products. Considering the large proportion of full-
length SMN that remains after activation of endogenous calpains
(Fig. 1A,B), it is likely that only a select population of SMN is
cleaved.
Calpains are present in both the cytoplasm and the nucleus,
however the vast majority of calpain substrates studied to date are
cytosolic. Currently, it is unclear if reportedly nuclear substrates of
calpain are actually cleaved in the nucleus following import [37].
The best characterized function of SMN is its role in the assembly
of snRNPs in the cytoplasm, after which a fraction of SMN is
thought to be imported into the nucleus, localizing within Cajal
bodies and gems [101,102]. We found that SMN is cleaved by
endogenous calpains in the cytoplasm, but not in the nucleus
(Fig. 6). Differences in calpain activity, SMN complex composition
or differential post-translational modification, such as phosphor-
ylation of nuclear SMN, might render it resistant to calpain
cleavage. SMN is phosphorylated in the cytoplasm [103] and
dephosphorylated in the nucleus by the nuclear phosphatase
PPM1G [104]. In addition, protein kinase A (PKA) has been
shown to phosphorylate SMN in vitro, at noncanonical sites [13].
How phosphorylation affects the calpain cleavage of SMN is
unknown, however it is worth consideration since phosphorylation
can affect susceptibility of calpain substrates and the activities of
calpain and calpastatin (reviewed in [35,37]).
The challenge now lies in determining how calpain might
regulate SMN function in vivo. We previously demonstrated that
depletion of SMN leads to both arborization defects and loss of
myofibril integrity, even in the presence of normal snRNP levels,
suggesting a tissue-specific function of SMN [26,34]. SMN
interacts genetically and physically with a-actinin [26,105] and
the SMN complex colocalizes with a-actinin at the myofibril Z-
disc [26,34]. Notably, over 20 muscle related diseases have been
attributed to mutations in sarcomeric proteins, including Z-disc
associated proteins, further underlining their importance [106].
Currently, the contribution of aberrant SMN muscle function to
SMA is not fully understood. Interestingly, Z-disc associated SMN
is a proteolytic target of calpain [34] however the fate of the
cleavage products in vivo is unknown. Considering that several Z-
disc proteins translocate from the sarcomere to the nucleus to
perform signaling functions [106], it is conceivable that SMN and
its cleavage products could have the same fate. Alternatively, it is
possible that SMN calpain cleavage products are subsequently
degraded by the proteasome. Indeed, sarcomeric proteins are only
accessible to the proteasome following initial cleavage by other
proteases such as caspases and calpains, indicating an important
role for these upstream proteases during muscle remodeling
[36,107]. In addition to normal myofibrillar turnover, calpains are
also implicated in muscle atrophy, as well as myogenesis [108].
Overexpression of calpastatin or depletion/inhibition of ubiqui-
tous calpains impairs myoblast migration and fusion
[109,110,111,112,113]. SMN has also been implicated in muscle
regeneration. Low levels of SMN inhibit myoblast fusion [25,114]
and satellite cells expressing SMND7 have limited regeneration
potential [115]. Whether calpains contribute to the muscle
atrophy seen in SMA patients by regulating a potential SMN
muscle-related role is unknown, but is an attractive possibility.
Finally, calpain activity could be important for the proper
functioning of SMN in neurons or may be affected as a result of
SMA. SMN is associated with hnRNP-R, Zbp1, eEF1A, profilin II
Figure 6. Endogenous calpain cleaves SMN in the cytoplasm. Cytoplasmic and nuclear extracts were prepared from U2-OS cells and used for
cell-free calpain assays. Western blotting was performed to detect calpain cleavage of SMN, calpain activation, and fractionation efficiency. (A)
Endogenous SMN was cleaved by endogenous calpain in the cytoplasm, but not in the nucleus. Extracts (30 mg) were left untreated (-), treated with
1 mM CaCl2 (+), or treated with calpain inhibitior (I) ALLN prior to CaCl2 addition. (B) Nuclear SMN was resistant to calpain cleavage even with the
addition of exogenous Calpain1. Extracts (30 mg) were left untreated (-), treated with 1 mM CaCl2 and 1U of exogenous Calpain1 (++), or treated with
calpain inhibitior (I) ALLN prior to addition of CaCl2 and Calpain1.
doi:10.1371/journal.pone.0015769.g006
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and b-actin mRNA and motoneurons isolated from severe SMA
mice show a reduction of hnRNP-R, b-actin mRNA, and actin
protein in the distal axons and growth cones, suggesting a role in
local protein synthesis and actin dynamics in neurons (reviewed in
[116]). SMA model mice display presynaptic and postsynaptic
NMJ defects, such as impaired synaptic vesicle release, abnormal
accumulation of presynaptic neurofilament protein (including
phospho-isoforms), reduced AChR cluster size, and small
myofibers [28,117,118,119,120]. In addition, a recent study
demonstrated that TVA muscles from SMA mice
(Smn-/-;SMN2;SMND7) have increased (,300%) asynchronous
release frequency in the nerve terminals, unless assayed in the
presence of EGTA. This suggests that there is a high increase in
intraterminal bulk Ca2+ in these mice [120]. It is tempting to
speculate that this increase in Ca2+ might affect the activity of
calpains and consequently contribute to the SMA phenotype.
Considering that calpain is involved in the dispersal of AChR
clusters [121,122] and that the dephosphorylated neurofilament
protein is a calpain substrate [123], it is possible that altered
calpain activity could lead to neurofilament accumulation and
AChR cluster defects seen in SMA synapses. Furthermore,
motoneurons isolated from severe SMA mice (Smn2/2; SMN2),
or those depleted of hnRNP-R, show a reduction in clustering of
N-type voltage-gated Ca2+ channels (Cav2.2 channels), resulting in
reduced Ca2+ transients in neuronal growth cones [124]. The
potential effect on calpain activity is unknown, however it is
noteworthy that, the Cavb3 subunit of the Cav2.2 channel is a
calpain substrate and its proteolytic cleavage may be essential for
regulation of the Ca2+ channel [125]. Overall, these observations
suggest aberrant calcium signaling in the motoneurons of SMA
mice. Such changes in calcium signaling could affect calpain
activity and thereby the proteolytic regulation of a subpopulation
of SMN in neurons.
Altogether, these relationships lead us to ask whether calpain
cleavage of SMN is a physiologically productive event, leading to
proper SMN function, versus a pathological result of aberrant
calpain activation. Regardless, either scenario is interesting. In this
study, we have laid the foundation for studying how calpain
cleaves SMN by unveiling several determinants of cleavage. The
next task at hand is to determine the physiological context under
which calpain might play a role in regulating SMN function. This
is a considerable challenge in view of the numerous putative
functions for SMN and calpains, as well as the likelihood that
calpain cleaves only a subpopulation of SMN in a context specific
manner. However, the potential contribution by calpains to SMA
pathology, indirectly, or directly through regulation of SMN,
warrants the effort.
Supporting Information
Figure S1 Prolines in the CCR region do not affect
calpain cleavage of SMN. Deletion or substitutions of proline
residues, P195-P199, were created in EGFP-SMN and transiently
expressed in U2-OS cells. Endogenous calpain cleavage assays and
subsequent Western analysis was performed to determine calpain
cleavage susceptibility. Mutations of these proline residues within
the CCR did not block calpain cleavage. Deletion of the prolines
did reduce the size of the C-terminal cleavage product, suggesting
the calpain cleavage site resides upstream of these residues.
(TIF)
Figure S2 Identification of major protein bands present
in the purified recombinant HIS6-SMN/GST-Gemin2
heterodimers preparation. (A) Coomassie stained gel of
HIS6-SMN/GST-Gemin2 heterodimers cleaved in vitro with
indicated units of Calpain1 for 1 h. at 30uC. Full-length SMN
(FL-SMN) as well as the N-terminal (N-SMN) and C-terminal (C-
SMN) cleavage products are indicated with arrows. The C-
terminal cleavage fragments were subjected to peptide fingerprint
analysis. Asterisks (*) indicate full-length and truncated GST-
Gemin2 proteins (see Fig. 3). (B) Western blot analysis of in vitro
calpain assays. Antibodies recognizing the N- or C-terminus of
SMN detected FL-SMN and SMN calpain cleavage products. The
fraction of SMN cleavage was directly proportional to the amount
of exogenous Calpain1 added. Antibodies recognizing Gemin2 or
GST detected full-length and truncated GST-Gemin2 proteins.
(TIF)
Figure S3 MS/MS spectra obtained from the C-termi-
nal calpain cleavage product of SMN. Recombinant HIS6-
SMN/GST-Gemin2 heterodimers were treated with 1U of
Calpain1, subjected to reduction and alkylation, and resolved on a
Coomassie stained SDS-PAGE gel. The C-terminal calpain cleavage
product was excised from the gel, typsinized, and the resul-
tant peptides were analyzed by MALDI TOF/TOF mass spec-
trometry. Four peptides (A-D) were matched to SMN by peptide
mass and MS/MS fragmentation. (A) S192*FLPPPPPMoxPGPR*L205,
m/z = 1318.7067 (B) F193*LPPPPPMPGPR*L205, m/z = 1155.6343
(C) F193*LPPPPPMoxPGPR*L205, m/z = 1171.6345 (D) R204*LGPG-
KPGLK*F214, m/z = 866.5449. Two peptides (A, C) were in oxidized
form (ox). Asterisks indicate the proteolytic sites. Non-tryptic
peptides (A-C) reveal the calpain cleavage sites. Peptide m/z for
each peptide is reported.
(TIF)
Figure S4 MS/MS spectra obtained from the C-termi-
nal calpain cleavage product of SMN. Recombinant HIS6-
SMN/GST-Gemin2 heterodimers were treated with 2U of
Calpain1, subjected to reduction and alkylation, and resolved on
a Coomassie stained SDS-PAGE gel. The C-terminal calpain
cleavage product was excised from the gel, typsinized, and the
resultant peptides were were analyzed by MALDI TOF/TOF
mass spectrometry. Five peptides (A-E) were matched to SMN1 by
peptide mass and MS/MS fragmentation. (A) S192*FLPPPP-
PMPGPR*L205, m/z = 1302.7100 (B) S192*FLPPPPPMoxPGP-
R*L205, m/z = 1318.7010 (C) F193*LPPPPPMPGPR*L205, m/
z = 1155.6340 (D) F193*LPPPPPMoxPGPR*L205, m/z = 1171.6300
(E) R204*LGPGKPGLK*F214, m/z = 866.5366. Two peptides (B, D)
were in oxidized form (ox). Asterisks indicate the proteolysis sites.
Non-tryptic peptides (A–D) reveal the calpain cleavage sites.
Peptide m/z for each peptide is reported.
(TIF)
Figure S5 Calpain susceptibility of SMND7 and
SMND7+EMLA. Mutations were created in EGFP-SMN and
transiently expressed in U2-OS cells. Endogenous calpain cleavage
assays and subsequent Western analysis were performed to
determine calpain cleavage susceptibility. No obvious difference in
calpain cleavage was seen between SMND7 and SMND7+EMLA.
(TIF)
Figure S6 Calpain susceptibility of D30N and D44V
mutations in SMNex1-5. Mutations were created in EGFP-
SMNex1-5 and transiently expressed in U2-OS cells. Calpain
cleavage of full-length WT EGFP-SMN was assayed in parallel.
Endogenous calpain cleavage assays and subsequent Western
analyses were performed to determine calpain cleavage suscepti-
bility. (A) Antibodies recognizing the N-terminus of SMN detected
WT SMN proteins. (B) Anti-GFP antibodies were used to detect
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the D44V mutant protein. Results show that both WT and mutant
proteins were cleaved by calpain and produced similar N-terminal
cleavage products. These results suggest that the C-terminus is
important for availability of the calpain cleavage site. Further-
more, the data show that the cleavage site is located within
residues encoded by exons 1-5. Asterisk (*) indicates an additional
calpain cleavage product observed for the EGFP-SMNex1-5
truncation (WT and D44V). This additional calpain cleavage
product was only observed using anti-GFP antibodies. Cleavage
products observed in the untreated lysate suggest that the EGFP-
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